Valsartan and Edarbyclor drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Valsartan and Edarbyclor. Common interactions include diarrhoea among females and blindness unilateral among males.

The phase IV clinical study analyzes what interactions people who take Valsartan and Edarbyclor have. It is created by eHealthMe based on reports of 23 people who take Valsartan and Edarbyclor from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jun, 30, 2022

23 people who take Valsartan and Edarbyclor together, and have interactions are studied.


What is Valsartan?

Valsartan has active ingredients of valsartan. It is often used in high blood pressure. eHealthMe is studying from 49,081 Valsartan users for its effectiveness, alternative drugs and more.

What is Edarbyclor?

Edarbyclor has active ingredients of azilsartan kamedoxomil; chlorthalidone. It is often used in high blood pressure. eHealthMe is studying from 1,203 Edarbyclor users for its effectiveness, alternative drugs and more.

Number of Valsartan and Edarbyclor reports submitted per year:

Valsartan and Edarbyclor drug interactions.

Common Valsartan and Edarbyclor drug interactions by gender *:

female:

  1. Diarrhoea
  2. Cardiac failure congestive
  3. Gastrooesophageal reflux disease
  4. Nightmare
  5. Vascular occlusion
  6. Drug hypersensitivity
  7. Pneumonia
  8. Somnambulism
  9. Amnesia
  10. Blood pressure decreased

male:

  1. Blindness unilateral
  2. Cough
  3. Eye disorder
  4. Glaucoma
  5. Intraocular pressure decreased
  6. Retinal disorder
  7. Throat irritation
  8. Chronic kidney disease
  9. Nephrogenic anaemia
  10. Renal failure

Common Valsartan and Edarbyclor drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Urinary tract infection
  2. Vision blurred
  3. Neoplasm progression

60+:

  1. Blood pressure decreased
  2. Chest discomfort
  3. Dizziness
  4. Heart rate increased
  5. Malaise
  6. Chronic kidney disease
  7. Fibromyalgia
  8. Nephrogenic anaemia
  9. Renal failure

Common conditions people have *:

  1. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 9 people, 39.13%
  2. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 9 people, 39.13%
  3. Pain: 3 people, 13.04%

* Approximation only. Some reports may have incomplete information.

Do you take Valsartan and Edarbyclor?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Valsartan and Edarbyclor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Valsartan interactions:

Browse all interactions between Valsartan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Edarbyclor interactions:

Browse all interactions between Edarbyclor and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on valsartan and azilsartan kamedoxomil; chlorthalidone (the active ingredients of Valsartan and Edarbyclor, respectively), and Valsartan and Edarbyclor (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: